List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Overview
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Celltrion Inc
ChemoCentryx Inc
GlaxoSmithKline Plc
Humanigen Inc
InflaRx NV
Nichi-Iko Pharmaceutical Co Ltd
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HGEN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Celltrion Inc, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by ChemoCentryx Inc, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Humanigen Inc, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by InflaRx NV, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects, H1 2019
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Mentioned
• Bristol-Myers Squibb Co
• Celltrion Inc
• ChemoCentryx Inc
• GlaxoSmithKline Plc
• Humanigen Inc
• InflaRx NV
• Nichi-Iko Pharmaceutical Co Ltd